Elite Pharmaceuticals Inc. (OTCMKTS:ELTP - Get Free Report)'s stock price crossed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $0.57 and traded as high as $0.62. Elite Pharmaceuticals shares last traded at $0.62, with a volume of 1,084,598 shares changing hands.
Elite Pharmaceuticals Stock Down 0.4%
The firm has a 50 day moving average of $0.58 and a two-hundred day moving average of $0.51. The company has a debt-to-equity ratio of 0.08, a quick ratio of 3.50 and a current ratio of 4.88.
Elite Pharmaceuticals (OTCMKTS:ELTP - Get Free Report) last announced its earnings results on Monday, June 30th. The specialty pharmaceutical company reported $0.01 earnings per share for the quarter. Elite Pharmaceuticals had a positive return on equity of 3.96% and a negative net margin of 5.13%. The firm had revenue of $32.00 million during the quarter.
Elite Pharmaceuticals Company Profile
(
Get Free Report)
Elite Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals.
Featured Stories
Before you consider Elite Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elite Pharmaceuticals wasn't on the list.
While Elite Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
